Khataminia Masoud, Najmeddin Farhad, Najafi Atabak, Sharifnia Hamidreza, Ahmadi Arezoo, Sahebnasagh Adeleh, Mojtahedzadeh Mojtaba
Student Research Committee, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
J Pharm Health Care Sci. 2021 Oct 11;7(1):37. doi: 10.1186/s40780-021-00219-6.
Keeping the heart rate within the normal range has improved the survival of septic shock patients. Amiodarone could target the underlying pathophysiology of sepsis-induced tachycardia. This study aimed to determine whether amiodarone is effective in controlling the heart rate in critically ill patients with septic shock and sustained tachycardia who were receiving vasopressor.
In this prospective, single-arm cohort study, 46 patients with septic shock and tachycardia were enrolled to receive a loading dose of amiodarone 150 mg, then continuous infusion of 1 mg/min. The primary outcome was the ability of amiodarone in rate control lower than 95 beats per minute (BPM) and maintaining it during 24-h study period. We also recorded the effect of amiodarone on hemodynamic indices as the secondary outcomes.
The results of the present study indicated a significant decrease in HR in septic shock patients for amiodarone, from 121.0 (116.5, 140.0) at baseline to 91.5(89.3, 108.0) at the end of the study period (p < 0.001). During the study period, a total of 26 (56.52%) of patients achieved the target heart rate lower than 95 BPM and maintained it during study period. Amiodarone decreased HR by 22.8 ± 13.7. While receiving amiodarone infusion, the values for heart rate, mean arterial pressure, cardiac index, norepinephrine infusion rate, and stroke volume index changed significantly between amiodarone initiation and 24-h follow-up (P < 0.001). Amiodarone was well tolerated, because this anti-arrhythmic agent did not increase the need for vasopressor and none of the patients experienced episodes of refractory hypotension.
This study showed that amiodarone infusion successfully reduced the heart rate in sepsis-induced tachycardia. The patients had improved hemodynamic state as indicated by an increase in cardiac index and SVI.
将心率维持在正常范围内可提高感染性休克患者的生存率。胺碘酮可针对脓毒症诱导的心动过速的潜在病理生理学机制。本研究旨在确定胺碘酮对正在接受血管升压药治疗的感染性休克和持续性心动过速的危重症患者控制心率是否有效。
在这项前瞻性单臂队列研究中,46例感染性休克和心动过速患者入选,接受150mg胺碘酮负荷剂量,然后以1mg/分钟的速度持续输注。主要结局是胺碘酮在24小时研究期间将心率控制在低于95次/分钟(BPM)并维持该水平的能力。我们还记录了胺碘酮对血流动力学指标的影响作为次要结局。
本研究结果表明,胺碘酮使感染性休克患者的心率显著降低,从基线时的121.0(116.5,140.0)降至研究期末的91.5(89.3,108.0)(p<0.001)。在研究期间,共有26例(56.52%)患者达到低于95BPM的目标心率并在研究期间维持该水平。胺碘酮使心率降低了22.8±13.7。在接受胺碘酮输注期间,从开始输注胺碘酮到24小时随访期间,心率、平均动脉压、心脏指数、去甲肾上腺素输注速率和每搏量指数的值发生了显著变化(P<0.001)。胺碘酮耐受性良好,因为这种抗心律失常药物没有增加对血管升压药的需求,且没有患者出现难治性低血压发作。
本研究表明,输注胺碘酮成功降低了脓毒症诱导的心动过速患者的心率。患者的血流动力学状态得到改善,表现为心脏指数和每搏量指数增加。